Gilead Sciences, Inc. Stock

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2024-05-24 EDT 5-day change 1st Jan Change
65.68 USD -0.74% Intraday chart for Gilead Sciences, Inc. -3.01% -18.92%
Sales 2024 * 27.61B 37.7B Sales 2025 * 27.99B 38.22B Capitalization 81.83B 112B
Net income 2024 * 403M 550M Net income 2025 * 6.35B 8.68B EV / Sales 2024 * 3.62 x
Net Debt 2024 * 18.15B 24.79B Net Debt 2025 * 12.68B 17.32B EV / Sales 2025 * 3.38 x
P/E ratio 2024 *
196 x
P/E ratio 2025 *
12.7 x
Employees 18,000
Yield 2024 *
4.72%
Yield 2025 *
4.94%
Free-Float 99.89%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.74%
1 week-3.01%
Current month+0.74%
1 month+0.40%
3 months-9.97%
6 months-12.87%
Current year-18.92%
More quotes
1 week
65.21
Extreme 65.21
67.90
1 month
64.33
Extreme 64.33
68.37
Current year
64.33
Extreme 64.33
87.87
1 year
64.33
Extreme 64.33
87.87
3 years
57.17
Extreme 57.165
89.74
5 years
56.56
Extreme 56.56
89.74
10 years
56.56
Extreme 56.56
123.37
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 19-02-28
Director of Finance/CFO 54 15-12-31
Chief Tech/Sci/R&D Officer - 21-04-11
Members of the board TitleAgeSince
Director/Board Member 69 20-10-16
Director/Board Member 71 17-12-31
Director/Board Member 65 01-31
More insiders
Date Price Change Volume
24-05-24 65.68 -0.74% 5,971,044
24-05-23 66.17 -2.40% 5,625,302
24-05-22 67.8 +0.76% 6,227,702
24-05-21 67.29 -0.90% 5,701,228
24-05-20 67.9 +0.27% 4,719,854

Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm

More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.68 USD
Average target price
82.77 USD
Spread / Average Target
+26.03%
Consensus